Aptose Biosciences Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 9 - Related party transactions (Details Textual)

Note 9 - Related party transactions (Details Textual) - USD ($)								9 Months Ended		35 Months Ended
	Sep. 11, 2024	Sep. 02, 2024	Aug. 27, 2024	Jun. 03, 2024	Jan. 31, 2024	Sep. 06, 2023	Nov. 04, 2021	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Dec. 31, 2023	Aug. 10, 2023
Schedule of Equity Method Investments [Line Items]
Common shares issued (in shares)	1,395,000
Financing costs including underwriting costs, professional fees and recognition of deferred financing costs				$ 408,000,000	$ 1,400,000
Underwriting costs (as percent)				7.00%
Common Stock, Shares Outstanding								19,521,183		19,521,183	7,942,363
Accrued liabilities								$ 7,512,000		$ 7,512,000	$ 8,829,000
Accounts payable								1,830,000		1,830,000	3,492,000
Public Offering [Member]
Schedule of Equity Method Investments [Line Items]
Common shares issued (in shares)					5,649,122
Private Placement [Member]
Schedule of Equity Method Investments [Line Items]
Warrants to purchase common shares, number of warrants				192,750
Over-Allotment Option [Member]
Schedule of Equity Method Investments [Line Items]
Common shares issued upon exercise of stock options					$ 736,842
Common Shares [Member] \| Warrant [Member]
Schedule of Equity Method Investments [Line Items]
Common warrants offering price					$ 1.71
Supply Agreement [Member]
Schedule of Equity Method Investments [Line Items]
Expenses								0	$ 3,100,000	7,100,000
Payment of supply costs										7,100,000
Accrued liabilities								0		0	0
Accounts payable								0		$ 0	$ 2,600,000
Hanmi Licensing Agreement [Member]
Schedule of Equity Method Investments [Line Items]
License Fee, Total							$ 12,500,000
Payments for License Fee							5,000,000
Stock Issued During Period, Value, Licensing Fee							$ 7,500,000
Hanmi Loan Agreement [Member]
Schedule of Equity Method Investments [Line Items]
Loan agreement amount			$ 10,000,000
Loan is repayable date			Jan. 31, 2027
Interest on loan paid								$ 51,000
Loan interest rate								6.00%		6.00%
Convertible debt conversion		$ 10,000,000
Hanmi Pharmaceuticals Co., Ltd. [Member]
Schedule of Equity Method Investments [Line Items]
Number of common shares held							215,703
Future milestone payments							$ 407,500,000
Proceeds from Issuance of Common Stock						$ 3,000,000
Underwriting costs (as percent)					7.00%
Professional Fees					$ 400,000
Common Stock, Shares Outstanding								2,989,415		2,989,415
Investment Owned, Balance, Shares							215,703
Payment of supply costs								$ 2,600,000	$ 4,500,000
Hanmi Pharmaceuticals Co., Ltd. [Member] \| Public Offering [Member]
Schedule of Equity Method Investments [Line Items]
Proceeds from Issuance of Common Stock					$ 9,700,000
Premium share price (as a percent)					11.00%
Hanmi Pharmaceuticals Co., Ltd. [Member] \| Private Placement [Member]
Schedule of Equity Method Investments [Line Items]
Proceeds from Issuance of Common Stock					$ 4,000,000
Common shares issued (in shares)					2,105,263
Shares Issued, Price Per Share					$ 1.9
Hanmi Pharmaceuticals Co., Ltd. [Member] \| Common Shares [Member]
Schedule of Equity Method Investments [Line Items]
Number of shares sold						668,449
Maximum [Member] \| Hanmi Pharmaceuticals Co., Ltd. [Member]
Schedule of Equity Method Investments [Line Items]
Investment for ownership interest												$ 7,000,000
Percentage of investment												19.99%